-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on TransMedics Group, Raises Price Target to $88

Benzinga·11/09/2026 21:00:57
Listen to the news
UBS analyst Patrick Wood maintains TransMedics Group (NASDAQ:TMDX) with a Neutral and raises the price target from $77 to $88.